Andrew Pollard | |
|---|---|
| Born | 29 August 1965 Tunbridge Wells, England, UK |
| Nationality | British |
| Alma mater | Guy's Hospital Medical School St Bartholomew’s Hospital Medical School Imperial College London |
| Occupation(s) | Professor of Paediatric Infection and Immunity |
| Known for | Chief Investigator on the University of Oxford COVID-19 Vaccine (ChAdOx-1 n-CoV-19), Director of Oxford Vaccine Group, Chair of JCVI |
| Scientific career | |
| Institutions | University of Oxford |
| Thesis | Age-related changes in immunity to Neisseria meningitidis (1999) |
| Website | www |
Sir Andrew John Pollard FHEA FMedSci FRS (born 29 August 1965) is the Ashall Professor of Infection & Immunity at the University of Oxford[1] and a Fellow of St Cross College, Oxford.[2] He is an Honorary Consultant Paediatrician at John Radcliffe Hospital and the Director of the Oxford Vaccine Group.[3] He is the Chief Investigator on the University of Oxford COVID-19 Vaccine (ChAdOx-1 n-CoV-19) trials and has led research on vaccines for many life-threatening infectious diseases including typhoid fever, Neisseria meningitidis, Haemophilus influenzae type b, streptococcus pneumoniae, pertussis, influenza, rabies, and Ebola.[4]
Because "In order to prevent any perceived conflict of interest it was agreed that the Joint Committee on Vaccination and Immunisation (JCVI) Chair (Professor Andrew Pollard), who is involved in the development of a SARS-CoV-2 vaccine at Oxford, would recuse himself from all JCVI COVID-19 meetings",[5] JCVI Deputy Chair Professor Anthony Harnden acts in his stead on these matters.
Pollard was awarded the coveted James Spence Medal[6] by the Royal College of Paediatrics and Child Health (RCPCH) in 2022.[7]